Interní Med. 2016; 18(3): 130-133 | DOI: 10.36290/int.2016.030

Recommendations for care of patients with diabetes and kidney impairment

MUDr. Jan Vachek, MUDr. PhDr. Oskar Zakiyanov, Ph.D., prof. MUDr. Vladimír Tesař, DrSc., MBA, FASN, FERA
Klinika nefrologie 1. LF UK a VFN v Praze

The attending physician treating a patient with diabetes is frequently confronted with the simultaneous presence of both diseases:

diabetes and reduced kidney function. Patients with diabetes are at high risk of developing kidney disease in comparison with

general population, and timely evaluation for the decline of renal function in these patients is very important. Many metabolic

changes namely the enhanced catabolism at progressive loss of renal function, diminished gluconeogenesis and glycogenolysis,

pharmacokinetic changes of medicaments including antidiabetics should be taken into account at the decrease of glomerular

filtration rate below 60 ml/min (1 ml/sec). Comprehensive knowledge of the antidiabetic drugs mechanism of action and their

metabolisms seems to be absolutely necessary to prevent side effects of such therapy and patient damage, specifically hypoglycaemia

and drug interactions. Management and treatment of diabetes becomes a multidisciplinary task with a participation

of a nephrologist. The wide role of nephrologist in the care of diabetic patient is not only limited to the management of diabetic

complications and choice of appropriate antidiabetic drug therapy adjusted to renal function, but also includes verification of

kidney diagnosis and exclusion of other or coincidence nephropathy.

Keywords: diabetes (DM), chronic kidney disease (CKD), diabetic nephropathy, novel antidiabetics

Published: July 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vachek J, Zakiyanov O, Tesař V. Recommendations for care of patients with diabetes and kidney impairment. Interní Med. 2016;18(3):130-133. doi: 10.36290/int.2016.030.
Download citation

References

  1. Avogaro A, Schernthaner G. Achieving glycemic control in patients with type 2 diabetes and renal impairment. Acta Diabetol. 2013; 50: 283-291. Go to original source... Go to PubMed...
  2. Hartmann B, Czock D, Keller F. Drug therapy in patients with chronic renal failure. Dtsch Arztebl Int 2010; 107: 647-655. Go to original source...
  3. Zang M, Zuccollo A, Hou X, et al. AMP-activated protein kinase resistant human is required for the lipid-lowering effect of metformin in insulin HepG2 cells. J Biol Chem 2004; 279: 47898-47905. Go to original source...
  4. Duong JK, Kumar SS, Kirkpatrick CM, Greenup LC, Arora M, Lee TC, Timmins P, Graham GG, Furlong TJ, Greenfield JR, Williams KM, Day RO. Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function. Clin Pharmacokinet 2013; 52: 373-84. Go to original source... Go to PubMed...
  5. Eppenga WL, Lalmohamed A, Geerts AF, Derijks HJ, Wensing M, Egberts A, De Smet PA, de Vries F. Risk of lactic acidosis or elevated lactate concentrations in metformin users with renal impairment: a population-based cohort study. Diabetes Care 2014; 37: 2218-24. Go to original source...
  6. Flory JH, Hennessy S. Metformin use reduction in mild to moderate renal impairment: possible inappropriate curbing of use based on food and drug administration contraindications. JAMA Intern Med 2015; 175: 458-459. Go to original source...
  7. Inzucchi SE, Lipska KJ, Mayo H, et al. Metformin in Patients With Type 2 Diabetes and Kidney Disease. A Systematic Review. JAMA. 2014; 312(24): 2668-2675. Go to original source...
  8. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355: 2427-2443. Go to original source...
  9. Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial. 2004; 17: 365-370. Go to original source...
  10. Balant L, Zahnd G, Gorgia A et al. Pharmacokinetics of glipizide in man: influence of renal insufficiency. Diabetologia 1973: 331-338. Go to original source...
  11. Campbell DB, Lavielle R, Nathan C. The mode of action and clinical pharmacology of gliclazide: a review. Diabetes Res Clin Pract 1991; 14: S21-S36. Go to original source...
  12. Palmer KJ, Brogden RN. Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. Drugs 1993; 46: 92-125. Go to original source... Go to PubMed...
  13. Drouin P, Standl E. Gliclazide modified release: results of a 2-year study in patients with type 2 diabetes. Diabetes Obes Metab 2004; 6: 414-421. Go to original source...
  14. Rosenkranz B, Profozic V, Metelko Z, et al. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia 1996; 39: 1617-1624. Go to original source...
  15. Pearson JG, Antal EJ, Raehl CL, et al. Pharmacokinetic disposition of 14C-glyburide in patients with varying renal function. Clin Pharmacol Ther 1986; 39: 318-324. Go to original source...
  16. Hasslacher C; Multinational Repaglinide Renal Study Group (2003) Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care 26: 886-891. Go to original source...
  17. Linnebjerg H, Kothare PA, Park S, et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007; 64: 317-327. Go to original source...
  18. Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol 2009: 68: 898-905. Go to original source...
  19. Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab. 2011; 13: 947-54. Go to original source...
  20. Nowicki M, Rychlik I, Haller H, Warren M, Suchower L, Gause-Nilsson I, et al. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract. 2011; 65: 1230-1239. Go to original source... Go to PubMed...
  21. Graefe-Mody U, Friedrich C, Port A, Ring A, Retlich S, Heise T, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab. 2011; 13: 939-946. Go to original source...
  22. Charpentier G, Riveline JP, Varroud-Vial M. Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab 2000; 26(Suppl 4): 73-85.
  23. Lewin A, DeFronzo RA, Patel S, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care 2015; 38: 394-402. Go to original source... Go to PubMed...
  24. Zinman, B, Wanner, C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med.




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.